<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657020</url>
  </required_header>
  <id_info>
    <org_study_id>S3250493</org_study_id>
    <nct_id>NCT00657020</nct_id>
  </id_info>
  <brief_title>Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms</brief_title>
  <official_title>Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, double blind, randomized, placebo controlled, two-treatments, two-period
      crossover study conducted in adult smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to use blood oxygen level-dependent (BOLD) functional
      Magnetic Resonance Imaging (fMRI) in abstinent smokers to directly evaluate the effect of the
      4 milligrams (mg) nicotine lozenge on brain activation associated with visual attention. The
      experimental task featured 3 conditions: 1. a highly demanding cognitive/attention task, 2. a
      simple cognitive/attention task, and 3. simply look at a '+' symbol. During the experiment
      these conditions are each presented a number of times in an alternating manner while
      acquiring images.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task</measure>
    <time_frame>Approximately 2 hours post dose administration</time_frame>
    <description>In RVIP task, participant responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participant responded to single occurrences of the number &quot;0&quot;. BOLD fMRI signals evaluated different brain regions of interest (ROI) during RVIP task. Brain ROIs identified were right and left anterior insula, anterior putamen, parietal cortex, premotor cortex, visual cortex, dorsal anterior cingulate cortex, substantia nigra and thalamus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Response Time for Correct Responses During RVIP Task</measure>
    <time_frame>Approximately 2 hours post dose administration</time_frame>
    <description>During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participants responded to single occurrences of the number &quot;0&quot;. Mean response time for correct responses was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Correct Responses During RVIP Task</measure>
    <time_frame>Approximately 2 hours post dose administration</time_frame>
    <description>Percentage of correct responses during RVIP task was determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Mean Change in BOLD Scores During Divided Attention (DIA) Task</measure>
    <time_frame>Approximately 2 hours post dose admininstration</time_frame>
    <description>BOLD fMRI signals evaluated different brain ROIs during DIA task which comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Brain ROIs were right and left parietal cortex, visual cortex, superior occipital cortex and right premotor cortex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Response Time for Correct Responses During DIA Task</measure>
    <time_frame>Approximately 2 hours post dose administration</time_frame>
    <description>DIA task comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Mean response time for correct responses was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Correct Responses During DIA Task</measure>
    <time_frame>Approximately 2 hours post dose administration</time_frame>
    <description>Mean percentage of correct responses during DIA task was determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Nicotine lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo lozenge</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo lozenge to be placed in mouth and suck to dissolution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Nicotine lozenge containing 4 mg of nicotine</description>
    <arm_group_label>Nicotine lozenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo lozenge</description>
    <arm_group_label>Placebo lozenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight and size

               1. Body mass index (BMI) within the range 19.0-32.0 kg/m.

               2. Able to fit comfortably within the MR scanner.

          -  Smoking Status

               1. Cigarette smokers that consume their first manufactured cigarette (i.e., not self
                  rolled cigarettes) within 30 min of waking.

               2. Individuals who have smoked regularly for at least a year.

          -  Females of childbearing potential who are, in the opinion of the investigator,
             practicing a reliable method of contraception.

          -  Understands and is willing, able and likely to comply with all study procedures and
             restrictions.

          -  Good general health with (in the opinion of the examining study doctor) no clinically
             significant and relevant abnormalities of medical history, physical examination or
             clinical laboratory test.

          -  Demonstrates understanding of the study and willingness to participate as evidenced by
             voluntary written informed consent and has received a signed and dated copy of the
             informed consent form.

        Exclusion Criteria:

          -  Women who are pregnant or who have a positive urine pregnancy test or

          -  who are breast-feeding.

          -  Disease/Illness

               1. Any clinically significant medical history or abnormality found on physical
                  examination, laboratory assessment or electrocardiogram (ECG) at screening which,
                  in the opinion of the investigator, could interfere with the interpretation of
                  efficacy or safety data or which otherwise would contraindicate participation in
                  a clinical trial.

               2. Current or recent history or presence of a neurological diagnosis (not limited to
                  but including for example, stroke, traumatic brain injury, carotid arterial
                  sclerotic disease, epilepsy, space occupying lesions, multiple sclerosis,
                  Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia,
                  major depression etc.) that may influence the outcome or analysis of the scan
                  results.

          -  Contraindications to MR scanning

               1. Intracranial aneurysm clips

               2. History of intra-orbital metal fragments that have not been removed by a doctor
                  (as confirmed by orbital X-Ray).

               3. Inner ear implants.

               4. Tattoos with metal containing inks or piercings that can not be removed except
                  those, which, in the opinion of the Investigator, will not interfere with the
                  study procedures or compromise safety.

               5. History of claustrophobia or subject feels unable to lie still on their back for
                  a period of 90 min in the MR scanner.

               6. Presence of a cardiac pacemaker or other electronic device or ferromagnetic metal
                  foreign bodies in vulnerable positions as assessed by a standard pre-MRI
                  questionnaire supported by plain X-Rays where appropriate.

          -  Prior/Concomitant Medication

               1. Use of any central nervous system (CNS) active, prescription medication within 14
                  days of first treatment visit.

               2. Use of any over the counter (OTC) medication within 14 days of each treatment
                  visit except those, which, in the opinion of the Investigator, will not interfere
                  with the study procedures or compromise safety. Paracetamol (up to 2 g) may be
                  taken up to 24 hrs prior to each treatment visit.

               3. Current use of any nicotine replacement therapy.

          -  Clinical Study/Experimental Medication

               1. Participation in another clinical study or receipt of an investigational drug
                  within 3 months of the first treatment visit.

               2. Previous participation in this study.

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients.

          -  Substance abuse

               1. History of regular alcohol consumption exceeding an average weekly intake of more
                  than 14 units per week for females, 21 units per week for males, or an average
                  daily intake greater than 2 units for females and 3 units for males.

               2. Past history of drug abuse, excluding nicotine, or has tested positive for urine
                  drugs of abuse at the screening or either treatment visit.

          -  Consumption of any alcoholic beverages within 24 hours of the treatment visits (as
             indicated by either a positive breath alcohol test or in the opinion of the
             Investigator).

          -  Consumption of large quantities of xanthine containing beverages (e.g., coffee, tea,
             cola, chocolate etc, more than an average of five cups or glasses per day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <results_first_submitted>October 12, 2009</results_first_submitted>
  <results_first_submitted_qc>March 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2010</results_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>therapy</keyword>
  <keyword>fMRI/EEG</keyword>
  <keyword>replacement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 45 participants were screened, 22 were considered screen failures. Investigators identified brain regions showing significant blood oxygen-level dependent (BOLD) activation associated with attention in each participant using Functional Magnetic Resonance Imaging (fMRI). Hence, participants categorized into high/low attention conditions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4 mg Nicotine Lozenge Then Placebo Lozenge</title>
          <description>Participants received nicotine lozenge containing 4 milligrams (mg) of nicotine in Period I and placebo lozenge in Period II.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Lozenge Then 4 mg Nicotine Lozenge</title>
          <description>Participants received placebo lozenge in Period I and nicotine 4 mg lozenge in Period II.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PERIOD 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>PERIOD 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Participants</title>
          <description>All randomized participants who receive study treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.82" spread="8.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task</title>
        <description>In RVIP task, participant responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participant responded to single occurrences of the number “0”. BOLD fMRI signals evaluated different brain regions of interest (ROI) during RVIP task. Brain ROIs identified were right and left anterior insula, anterior putamen, parietal cortex, premotor cortex, visual cortex, dorsal anterior cingulate cortex, substantia nigra and thalamus.</description>
        <time_frame>Approximately 2 hours post dose administration</time_frame>
        <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention condition and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention condition and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention condition and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention condition and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task</title>
          <description>In RVIP task, participant responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participant responded to single occurrences of the number “0”. BOLD fMRI signals evaluated different brain regions of interest (ROI) during RVIP task. Brain ROIs identified were right and left anterior insula, anterior putamen, parietal cortex, premotor cortex, visual cortex, dorsal anterior cingulate cortex, substantia nigra and thalamus.</description>
          <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
          <units>Percentage change in BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BOLD - Left Anterior Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.21"/>
                    <measurement group_id="O2" value="0.2" spread="0.27"/>
                    <measurement group_id="O3" value="0.7" spread="0.48"/>
                    <measurement group_id="O4" value="0.7" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Anterior Putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.20"/>
                    <measurement group_id="O2" value="0.1" spread="0.36"/>
                    <measurement group_id="O3" value="0.3" spread="0.27"/>
                    <measurement group_id="O4" value="0.3" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Dorsal Anterior Cingulate Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.39"/>
                    <measurement group_id="O2" value="0.4" spread="0.31"/>
                    <measurement group_id="O3" value="1.4" spread="0.70"/>
                    <measurement group_id="O4" value="1.0" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Dorsolateral Pre-Frontal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.29"/>
                    <measurement group_id="O2" value="0.1" spread="0.25"/>
                    <measurement group_id="O3" value="0.7" spread="0.77"/>
                    <measurement group_id="O4" value="0.7" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Parietal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.49"/>
                    <measurement group_id="O2" value="0.2" spread="0.37"/>
                    <measurement group_id="O3" value="1.5" spread="0.90"/>
                    <measurement group_id="O4" value="1.2" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Premotor Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.27"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                    <measurement group_id="O3" value="0.9" spread="0.69"/>
                    <measurement group_id="O4" value="0.7" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Substantia Nigra/Ventral Tegemental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.18"/>
                    <measurement group_id="O2" value="0.1" spread="0.29"/>
                    <measurement group_id="O3" value="0.4" spread="0.28"/>
                    <measurement group_id="O4" value="0.3" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.24"/>
                    <measurement group_id="O2" value="0.1" spread="0.36"/>
                    <measurement group_id="O3" value="0.5" spread="0.36"/>
                    <measurement group_id="O4" value="0.6" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Left Visual Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.72"/>
                    <measurement group_id="O2" value="0.9" spread="0.73"/>
                    <measurement group_id="O3" value="1.6" spread="0.73"/>
                    <measurement group_id="O4" value="1.9" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Anterior Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.18"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                    <measurement group_id="O3" value="0.5" spread="0.35"/>
                    <measurement group_id="O4" value="0.5" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Dorsal Anterior Cingulate Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.34"/>
                    <measurement group_id="O2" value="0.2" spread="0.17"/>
                    <measurement group_id="O3" value="0.8" spread="0.57"/>
                    <measurement group_id="O4" value="0.8" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Dorsolateral Pre-Frontal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.45"/>
                    <measurement group_id="O2" value="0.2" spread="0.37"/>
                    <measurement group_id="O3" value="1.0" spread="0.85"/>
                    <measurement group_id="O4" value="0.8" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Parietal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.46"/>
                    <measurement group_id="O2" value="0.2" spread="0.52"/>
                    <measurement group_id="O3" value="1.1" spread="0.62"/>
                    <measurement group_id="O4" value="1.2" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Premotor Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.47"/>
                    <measurement group_id="O2" value="0.2" spread="0.33"/>
                    <measurement group_id="O3" value="0.7" spread="0.61"/>
                    <measurement group_id="O4" value="0.8" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.22"/>
                    <measurement group_id="O2" value="0.0" spread="0.44"/>
                    <measurement group_id="O3" value="0.7" spread="0.44"/>
                    <measurement group_id="O4" value="0.6" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BOLD - Right Visual Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.44"/>
                    <measurement group_id="O2" value="-0.1" spread="0.32"/>
                    <measurement group_id="O3" value="0.4" spread="0.43"/>
                    <measurement group_id="O4" value="0.3" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of Interest is left anterior insula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2960</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left anterior insula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3450</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left anterior putamen.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1192</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left anterior putamen.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6639</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left dorsal anterior cingulate cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8295</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left dorsal anterior cingulate cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left dorsolateral pre-frontal cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7153</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left dorsolateral pre-frontal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8511</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left parietal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4228</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left parietal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0611</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left premotor cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9879</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left premotor cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2065</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left substantia nigra/ventral tegmental area</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1837</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left substantia nigra/ventral tegmental area</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8195</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left thalamus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6420</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left thalamus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7475</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left visual cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9049</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left visual cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1830</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5318</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9588</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right dorsal anterior cingulate cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7551</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right dorsal anterior cingulate cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7895</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right dorsolateral pre-frontal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9494</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right dorsolateral pre-frontal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4482</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right parietal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9343</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right parietal cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7711</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right premotor cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4755</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right premotor cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3982</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right thalamus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4622</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right thalamus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4604</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right visual cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2485</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right visual cortex</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1931</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Response Time for Correct Responses During RVIP Task</title>
        <description>During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participants responded to single occurrences of the number &quot;0&quot;. Mean response time for correct responses was determined.</description>
        <time_frame>Approximately 2 hours post dose administration</time_frame>
        <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention condition and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention condition and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention condition and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention condition and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Response Time for Correct Responses During RVIP Task</title>
          <description>During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participants responded to single occurrences of the number &quot;0&quot;. Mean response time for correct responses was determined.</description>
          <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.05"/>
                    <measurement group_id="O2" value="0.5" spread="0.05"/>
                    <measurement group_id="O3" value="0.5" spread="0.08"/>
                    <measurement group_id="O4" value="0.5" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered the response time of treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4535</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered the response time of treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1811</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Correct Responses During RVIP Task</title>
        <description>Percentage of correct responses during RVIP task was determined</description>
        <time_frame>Approximately 2 hours post dose administration</time_frame>
        <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention conditions and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention conditions and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Correct Responses During RVIP Task</title>
          <description>Percentage of correct responses during RVIP task was determined</description>
          <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
          <units>Percentage of responses correct</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" spread="5.27"/>
                    <measurement group_id="O2" value="91.1" spread="4.32"/>
                    <measurement group_id="O3" value="62.4" spread="18.51"/>
                    <measurement group_id="O4" value="54.1" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6261</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0106</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Mean Change in BOLD Scores During Divided Attention (DIA) Task</title>
        <description>BOLD fMRI signals evaluated different brain ROIs during DIA task which comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Brain ROIs were right and left parietal cortex, visual cortex, superior occipital cortex and right premotor cortex.</description>
        <time_frame>Approximately 2 hours post dose admininstration</time_frame>
        <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention conditions and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention conditions and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Mean Change in BOLD Scores During Divided Attention (DIA) Task</title>
          <description>BOLD fMRI signals evaluated different brain ROIs during DIA task which comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Brain ROIs were right and left parietal cortex, visual cortex, superior occipital cortex and right premotor cortex.</description>
          <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
          <units>Percentage change in BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Parietal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.39"/>
                    <measurement group_id="O2" value="0.1" spread="0.33"/>
                    <measurement group_id="O3" value="0.7" spread="0.44"/>
                    <measurement group_id="O4" value="0.6" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Superior Occipital Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.32"/>
                    <measurement group_id="O2" value="0.0" spread="0.28"/>
                    <measurement group_id="O3" value="0.4" spread="0.40"/>
                    <measurement group_id="O4" value="0.4" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Visual Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.48"/>
                    <measurement group_id="O2" value="-0.1" spread="0.41"/>
                    <measurement group_id="O3" value="0.8" spread="0.42"/>
                    <measurement group_id="O4" value="0.6" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Parietal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.55"/>
                    <measurement group_id="O2" value="-0.1" spread="0.63"/>
                    <measurement group_id="O3" value="0.5" spread="0.45"/>
                    <measurement group_id="O4" value="0.5" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Premotor Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.35"/>
                    <measurement group_id="O2" value="0.2" spread="0.57"/>
                    <measurement group_id="O3" value="0.5" spread="0.33"/>
                    <measurement group_id="O4" value="0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Superior Occipital Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.37"/>
                    <measurement group_id="O2" value="0.0" spread="0.46"/>
                    <measurement group_id="O3" value="0.5" spread="0.43"/>
                    <measurement group_id="O4" value="0.5" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Visual Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.54"/>
                    <measurement group_id="O2" value="0.0" spread="0.68"/>
                    <measurement group_id="O3" value="1.0" spread="1.13"/>
                    <measurement group_id="O4" value="1.2" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left parietal cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5544</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left parietal cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6716</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left superior occipital cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7511</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left superior occipital cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7959</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left visual cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6418</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is left visual cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2205</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right parietal cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5135</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right parietal cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9781</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right premotor cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3755</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right premotor cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2612</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right superior occipital cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8486</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right superior occipital cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8318</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right visual cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7554</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Region of interest is right visual cortex.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5421</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Response Time for Correct Responses During DIA Task</title>
        <description>DIA task comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Mean response time for correct responses was determined.</description>
        <time_frame>Approximately 2 hours post dose administration</time_frame>
        <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention conditions and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention conditions and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Response Time for Correct Responses During DIA Task</title>
          <description>DIA task comprised of three conditions: i) Sustained visual attention wherein participant responded to letter &quot;s&quot; every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number &quot;8&quot; each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of &quot;s&quot; (visual) and &quot;8&quot; (auditory) simultaneously. Mean response time for correct responses was determined.</description>
          <population>Number of participants with complete imaging data on both treatments (nicotine and placebo).</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.04"/>
                    <measurement group_id="O2" value="0.5" spread="0.04"/>
                    <measurement group_id="O3" value="0.5" spread="0.04"/>
                    <measurement group_id="O4" value="0.5" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered response time of treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1963</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered response time of treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0959</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Correct Responses During DIA Task</title>
        <description>Mean percentage of correct responses during DIA task was determined.</description>
        <time_frame>Approximately 2 hours post dose administration</time_frame>
        <population>Number of subjects with complete imaging data on both treatments (nicotine and placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 1</title>
            <description>Participants in low attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge 1</title>
            <description>Participants in low attention conditions and received placebo lozenge.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 2</title>
            <description>Participants in high attention conditions and received 4 mg of nicotine lozenge.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge 2</title>
            <description>Participants in high attention conditions and received placebo lozenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Correct Responses During DIA Task</title>
          <description>Mean percentage of correct responses during DIA task was determined.</description>
          <population>Number of subjects with complete imaging data on both treatments (nicotine and placebo)</population>
          <units>Percentage of responses correct</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="0.97"/>
                    <measurement group_id="O2" value="47.8" spread="1.15"/>
                    <measurement group_id="O3" value="96.9" spread="3.48"/>
                    <measurement group_id="O4" value="95.9" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5400</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered the treatments in comparison to be equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1800</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Lozenge</title>
          <description>Participants in safety population received 4 mg of nicotine lozenge.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Lozenge</title>
          <description>Participants in safety population received placebo lozenge.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

